BG65132B1 - N-[5-[[[5-алкил-2-оксазолил]метил]тио]-2-тиазолил]- карбоксамидни производни, фьрмацевтичен състав и използването им като инхибитори на циклин зависими кинази - Google Patents

N-[5-[[[5-алкил-2-оксазолил]метил]тио]-2-тиазолил]- карбоксамидни производни, фьрмацевтичен състав и използването им като инхибитори на циклин зависими кинази Download PDF

Info

Publication number
BG65132B1
BG65132B1 BG107468A BG10746803A BG65132B1 BG 65132 B1 BG65132 B1 BG 65132B1 BG 107468 A BG107468 A BG 107468A BG 10746803 A BG10746803 A BG 10746803A BG 65132 B1 BG65132 B1 BG 65132B1
Authority
BG
Bulgaria
Prior art keywords
pharmaceutically acceptable
hydrochloride
maleate
trifluoroacetate
compound
Prior art date
Application number
BG107468A
Other languages
Bulgarian (bg)
English (en)
Other versions
BG107468A (en
Inventor
Raj Misra
Hai-Yun Xiao
Original Assignee
Bristol-Myers Squibb Company
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from US09/727,957 external-priority patent/US6515004B1/en
Priority claimed from US09/746,060 external-priority patent/US6414156B2/en
Application filed by Bristol-Myers Squibb Company filed Critical Bristol-Myers Squibb Company
Publication of BG107468A publication Critical patent/BG107468A/xx
Publication of BG65132B1 publication Critical patent/BG65132B1/bg

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/425—Thiazoles
    • A61K31/427—Thiazoles not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
    • A61K31/454—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. pimozide, domperidone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/14—Drugs for dermatological disorders for baldness or alopecia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Epidemiology (AREA)
  • Rheumatology (AREA)
  • Pain & Pain Management (AREA)
  • Hematology (AREA)
  • Diabetes (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Dermatology (AREA)
  • Transplantation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
BG107468A 2000-07-26 2003-01-16 N-[5-[[[5-алкил-2-оксазолил]метил]тио]-2-тиазолил]- карбоксамидни производни, фьрмацевтичен състав и използването им като инхибитори на циклин зависими кинази BG65132B1 (bg)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US61662700A 2000-07-26 2000-07-26
US09/727,957 US6515004B1 (en) 1999-12-15 2000-12-01 N-[5-[[[5-alkyl-2-oxazolyl]methyl]thio]-2-thiazolyl]-carboxamide inhibitors of cyclin dependent kinases
US09/746,060 US6414156B2 (en) 1998-10-21 2000-12-22 Process for preparing azacycloalkanoylaminothiazoles

Publications (2)

Publication Number Publication Date
BG107468A BG107468A (en) 2004-01-30
BG65132B1 true BG65132B1 (bg) 2007-03-30

Family

ID=27417184

Family Applications (1)

Application Number Title Priority Date Filing Date
BG107468A BG65132B1 (bg) 2000-07-26 2003-01-16 N-[5-[[[5-алкил-2-оксазолил]метил]тио]-2-тиазолил]- карбоксамидни производни, фьрмацевтичен състав и използването им като инхибитори на циклин зависими кинази

Country Status (26)

Country Link
EP (1) EP1303513A1 (sl)
JP (1) JP2004509857A (sl)
KR (1) KR20030016429A (sl)
CN (1) CN100457753C (sl)
AR (1) AR030563A1 (sl)
AU (1) AU2001259704A1 (sl)
BG (1) BG65132B1 (sl)
BR (1) BR0112674A (sl)
CA (1) CA2417254A1 (sl)
CZ (1) CZ2003237A3 (sl)
EE (1) EE200300041A (sl)
EG (1) EG24409A (sl)
GE (1) GEP20043367B (sl)
HR (1) HRP20030116A2 (sl)
HU (1) HUP0303698A2 (sl)
IL (2) IL153591A0 (sl)
LV (1) LV13037B (sl)
MX (1) MXPA03000774A (sl)
MY (1) MY129635A (sl)
NO (1) NO20030394L (sl)
PL (1) PL365170A1 (sl)
SI (1) SI21099A (sl)
SK (1) SK18392002A3 (sl)
TW (1) TWI302533B (sl)
WO (1) WO2002010162A1 (sl)
YU (1) YU4903A (sl)

Families Citing this family (25)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6414156B2 (en) 1998-10-21 2002-07-02 Bristol-Myers Squibb Company Process for preparing azacycloalkanoylaminothiazoles
EP2311818B1 (en) * 2002-02-28 2013-01-16 Novartis AG Combination of a 5-phenylthiazole compound as PI3 kinase inhibitor with an antiinflammatory, bronchodilatory or antihistamine drug
MY156407A (en) 2002-02-28 2016-02-26 Novartis Ag 5-phenylthiazole derivatives and use as p13 kinase inhibitors
CA2497539A1 (en) 2002-09-04 2004-03-18 Schering Corporation Novel pyrazolopyrimidines as cyclin dependent kinase inhibitors
US8673924B2 (en) 2002-09-04 2014-03-18 Merck Sharp & Dohme Corp. Substituted pyrazolo[1,5-a]pyrimidines as cyclin dependent kinase inhibitors
TWI344468B (en) 2002-09-04 2011-07-01 Schering Corp Novel pyrazolopyrimidines as cyclin dependent kinase inhibitors
US8580782B2 (en) 2002-09-04 2013-11-12 Merck Sharp & Dohme Corp. Substituted pyrazolo[1,5-a]pyrimidines as cyclin dependent kinase inhibitors
KR20050057520A (ko) 2002-09-23 2005-06-16 쉐링 코포레이션 사이클린 의존성 키나제 억제제로서의 이미다조피라진
TW200412967A (en) 2002-09-23 2004-08-01 Schering Corp Novel imidazopyrazines as cyclin dependent kinase inhibitors
GB0320197D0 (en) * 2003-08-28 2003-10-01 Novartis Ag Organic compounds
EP1555264A1 (en) * 2004-01-15 2005-07-20 Sireen AG Five-membered heterocyclic compounds as inhibitors of SRC family protein kinase.
DE102005008310A1 (de) * 2005-02-17 2006-08-24 Schering Ag Verwendung von CDKII Inhibitoren zur Fertilitätskontrolle
JP2009504756A (ja) * 2005-08-17 2009-02-05 シェーリング コーポレイション 新規な高親和性のチオフェンベースおよびフランベースのキナーゼリガンド
JP2009507843A (ja) 2005-09-09 2009-02-26 シェーリング コーポレイション アザ縮合サイクリン依存性キナーゼ阻害剤
KR20080063806A (ko) 2005-10-06 2008-07-07 쉐링 코포레이션 단백질 키나제 억제제로서의 피라졸로피리미딘
JP2009539846A (ja) * 2006-06-06 2009-11-19 ブリストル−ミエルス スクイッブ カンパニー Ｎ−［５−［［［５−（１，１−ジメチルエチル）−２−オキサゾリル］メチル］チオ］−２−チアゾリル］−４−ピペリジンカルボキサミドの結晶形
US20090175852A1 (en) 2006-06-06 2009-07-09 Schering Corporation Imidazopyrazines as protein kinase inhibitors
CN101568527A (zh) 2006-10-31 2009-10-28 先灵公司 作为蛋白激酶抑制剂的2-氨基噻唑-4-羧酰胺
JP5063700B2 (ja) 2006-10-31 2012-10-31 シェーリング コーポレイション アニリノピペラジン誘導体およびアニリノピペラジン誘導体を使用する方法
WO2008140724A1 (en) 2007-05-08 2008-11-20 Schering Corporation Methods of treatment using intravenous formulations comprising temozolomide
TW200922564A (en) 2007-09-10 2009-06-01 Curis Inc CDK inhibitors containing a zinc binding moiety
WO2010075542A1 (en) 2008-12-23 2010-07-01 Curis, Inc. Cdk inhibitors
WO2011025706A2 (en) 2009-08-26 2011-03-03 Schering Corporation Heterocyclic amide compounds as protein kinase inhibitors
WO2013148775A1 (en) 2012-03-30 2013-10-03 Merck Sharp & Dohme Corp. Predictive biomarker useful for cancer therapy mediated by a cdk inhibitor
US9944670B2 (en) * 2013-12-04 2018-04-17 Hangzhou Yuanchang Medical Sci-Tech Co., Ltd Gemcitabine derivatives, compositions comprising same and pharmaceutical applications thereof

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1999024416A1 (en) * 1997-11-12 1999-05-20 Bristol-Myers Squibb Company Aminothiazole inhibitors of cyclin dependent kinases
WO1999065884A1 (en) * 1998-06-18 1999-12-23 Bristol-Myers Squibb Company Carbon substituted aminothiazole inhibitors of cyclin dependent kinases

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6262096B1 (en) * 1997-11-12 2001-07-17 Bristol-Myers Squibb Company Aminothiazole inhibitors of cyclin dependent kinases
US6414156B2 (en) * 1998-10-21 2002-07-02 Bristol-Myers Squibb Company Process for preparing azacycloalkanoylaminothiazoles
MY125768A (en) * 1999-12-15 2006-08-30 Bristol Myers Squibb Co N-[5-[[[5-alkyl-2-oxazolyl]methyl]thio]-2-thiazolyl]-carboxamide inhibitors of cyclin dependent kinases

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1999024416A1 (en) * 1997-11-12 1999-05-20 Bristol-Myers Squibb Company Aminothiazole inhibitors of cyclin dependent kinases
WO1999065884A1 (en) * 1998-06-18 1999-12-23 Bristol-Myers Squibb Company Carbon substituted aminothiazole inhibitors of cyclin dependent kinases

Also Published As

Publication number Publication date
LV13037B (en) 2003-11-20
MY129635A (en) 2007-04-30
YU4903A (sh) 2006-03-03
HUP0303698A2 (hu) 2004-04-28
AR030563A1 (es) 2003-08-27
TWI302533B (en) 2008-11-01
HRP20030116A2 (en) 2005-02-28
EG24409A (en) 2009-05-20
EP1303513A1 (en) 2003-04-23
CN100457753C (zh) 2009-02-04
BR0112674A (pt) 2003-12-30
JP2004509857A (ja) 2004-04-02
IL153591A0 (en) 2003-07-06
SI21099A (sl) 2003-06-30
CZ2003237A3 (cs) 2003-06-18
KR20030016429A (ko) 2003-02-26
SK18392002A3 (sk) 2003-09-11
CA2417254A1 (en) 2002-02-07
PL365170A1 (en) 2004-12-27
EE200300041A (et) 2005-04-15
NO20030394L (no) 2003-03-03
MXPA03000774A (es) 2003-09-10
NO20030394D0 (no) 2003-01-24
CN1444584A (zh) 2003-09-24
WO2002010162A1 (en) 2002-02-07
BG107468A (en) 2004-01-30
AU2001259704A1 (en) 2002-02-13
GEP20043367B (en) 2004-06-10
IL153591A (en) 2009-07-20

Similar Documents

Publication Publication Date Title
BG65132B1 (bg) N-[5-[[[5-алкил-2-оксазолил]метил]тио]-2-тиазолил]- карбоксамидни производни, фьрмацевтичен състав и използването им като инхибитори на циклин зависими кинази
US6515004B1 (en) N-[5-[[[5-alkyl-2-oxazolyl]methyl]thio]-2-thiazolyl]-carboxamide inhibitors of cyclin dependent kinases
ZA200204349B (en) N-[5-[[[5-alkyl-2-oxazolyl]methyl]thio]-2-thiazolyl] carboxamide inhibitors of cyclin dependent kinases.
ES2236034T3 (es) N- (5-(((5-alquil-2-oxazolil)metil)tio)-2-tiazolil carboxamida inhibidores de las cinasas dependientes de ciclina.
JP4344084B2 (ja) サイクリン依存性キナーゼのアミノチアゾール系阻害剤
AU774381B2 (en) N-(5-(((5-alkyl-2-oxazolyl)methyl)thio)-2-thiazolyl)- carboxamide inhibitors of cyclin dependent kinases
CA2408448A1 (en) Indazoles substituted with 1,1-dioxoisothiazolidine useful as inhibitors of cell proliferation
BR112014004219B1 (pt) Pirano[3,2-d][1,3]tiazol, seu processo de fabricação, medicamento, e composição farmacêutica
TW200932221A (en) Imidazole carbonyl compounds
LT5106B (lt) Nuo ciklinų priklausomų kinazių n-[5-[[[5-alkil-2-oxazolil]metil]tio]-2-tiazolil]karboksamido inhibitoriai
JP6927959B2 (ja) ベンジリデングアニジン誘導体と化学療法剤の併用による癌の治療方法
KR20130100056A (ko) Ｋｓｐ 억제제로서의 트리아졸 화합물
ZA200300452B (en) N-[5-[[[5-alkyl-2-oxazolyl]methyl]thio]-2-thiazolyl] carboxamide inhibitors of cyclin dependent kinases.
KR100406634B1 (ko) 3,5-디아미노인다졸 유도체, 그의 제조방법 및 사이클린의존성 키나아제 저해제로서의 그의 용도
JP2023155223A (ja) Ｋｒａｓ ｇ１２ｃ阻害剤及びオーロラａ阻害剤を含む治療方法